Natalie Galanina - Search Results

Year	Number of Results
2008	1
2010	1
2011	1
2016	5
2017	5
2018	5
2019	2
2020	1
2024	0

1

Emerging role of checkpoint blockade therapy in lymphoma.

Galanina N, Kline J, Bishop MR. Galanina N, et al. Ther Adv Hematol. 2017 Feb;8(2):81-90. doi: 10.1177/2040620716673787. Epub 2017 Jan 22. Ther Adv Hematol. 2017. PMID: 28203344 Free PMC article. Review.

2

The evolving role of lenalidomide in non-Hodgkin lymphoma.

Galanina N, Petrich A, Nabhan C. Galanina N, et al. Leuk Lymphoma. 2016 Jul;57(7):1507-16. doi: 10.3109/10428194.2016.1146949. Epub 2016 Feb 22. Leuk Lymphoma. 2016. PMID: 26902680 Review.

3

Molecular predictors of response to therapy for breast cancer.

Galanina N, Bossuyt V, Harris LN. Galanina N, et al. Cancer J. 2011 Mar-Apr;17(2):96-103. doi: 10.1097/PPO.0b013e318212dee3. Cancer J. 2011. PMID: 21427553 Review.

4

Successful Treatment of HIV-Associated Kaposi Sarcoma with Immune Checkpoint Blockade.

Galanina N, Goodman AM, Cohen PR, Frampton GM, Kurzrock R. Galanina N, et al. Cancer Immunol Res. 2018 Oct;6(10):1129-1135. doi: 10.1158/2326-6066.CIR-18-0121. Epub 2018 Sep 7. Cancer Immunol Res. 2018. PMID: 30194084 Free PMC article.

5

Ofatumumab monotherapy in relapsed/refractory diffuse large B-cell non-Hodgkin lymphoma.

Galanina N, Jasielec J, Peace D, Smith SM, Nabhan C. Galanina N, et al. Leuk Lymphoma. 2017 Mar;58(3):752-753. doi: 10.1080/10428194.2016.1207764. Epub 2016 Jul 14. Leuk Lymphoma. 2017. PMID: 27415580 Clinical Trial. No abstract available.

6

Real-world data from a molecular tumor board demonstrates improved outcomes with a precision N-of-One strategy.

Kato S, Kim KH, Lim HJ, Boichard A, Nikanjam M, Weihe E, Kuo DJ, Eskander RN, Goodman A, Galanina N, Fanta PT, Schwab RB, Shatsky R, Plaxe SC, Sharabi A, Stites E, Adashek JJ, Okamura R, Lee S, Lippman SM, Sicklick JK, Kurzrock R. Kato S, et al. Among authors: galanina n. Nat Commun. 2020 Oct 2;11(1):4965. doi: 10.1038/s41467-020-18613-3. Nat Commun. 2020. PMID: 33009371 Free PMC article.

7

Successful implementation of genomically based treatment of chemotherapy refractory peripheral T-cell lymphoma (PTCL).

Galanina N, Kurzrock R. Galanina N, et al. Cancer Biol Ther. 2019;20(3):247-251. doi: 10.1080/15384047.2018.1523857. Epub 2018 Oct 11. Cancer Biol Ther. 2019. PMID: 30307363 Free PMC article.

8

University of Chicago phase II consortium trial of selumetinib (MEKi) demonstrates low tolerability and efficacy in relapsed DLBCL.

Galanina N, Smith SM, Liao C, Petrich A, Libao B, Gartenhaus R, Westin JR, Cohen KS, Knost JA, Stadler WM, Doyle A, Karrison T, Gordon LI, Evens AM. Galanina N, et al. Br J Haematol. 2018 Apr;181(2):264-267. doi: 10.1111/bjh.14544. Epub 2017 Apr 17. Br J Haematol. 2018. PMID: 28419407 Free PMC article. Clinical Trial. No abstract available.

9

Remembering the forgotten child: the role of immune checkpoint inhibition in patients with human immunod eficiency virus and cancer.

Adashek JJ, Junior PNA, Galanina N, Kurzrock R. Adashek JJ, et al. Among authors: galanina n. J Immunother Cancer. 2019 May 22;7(1):130. doi: 10.1186/s40425-019-0618-9. J Immunother Cancer. 2019. PMID: 31113482 Free PMC article.

10

Heightened BTK-dependent cell proliferation in unmutated chronic lymphocytic leukemia confers increased sensitivity to ibrutinib.

Guo A, Lu P, Galanina N, Nabhan C, Smith SM, Coleman M, Wang YL. Guo A, et al. Among authors: galanina n. Oncotarget. 2016 Jan 26;7(4):4598-610. doi: 10.18632/oncotarget.6727. Oncotarget. 2016. PMID: 26717038 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

18 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

18 results

Results by year